-
Posted by
Two Blokes Jun 6 -
Filed in
Stock
-
7 views
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.
